findmyKOL

William Ershler, MD

Basic profile

Inova Fairfax Hospital

ORCID↗NPI↗
✓ Full record
RegionFairfax, VA · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL type: NationalLatest publication2014Online presenceNot yet checkedPayments2021 onwardNIH funding1996–1996

William Ershler is an Oncology physician affiliated with Inova Fairfax Hospital. OpenAlex indexes 287 publications with 16,596 citations (h-index 64); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
287publications

Distinct works indexed by OpenAlex, matched via ORCID.

16,596citations

Total citations across indexed works.

64h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1996–1996

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

8501 Arlington Blvd Ste 340
Fairfax, VA 22031

Telephone

703-207-0733

Provider last certified this registry record 16 Oct 2020.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    76.1%
    Thrombopoietin Receptor Agonist39.1%
    Promacta100%
    Part D<11 patients
    Factor Xa inhibitor37%
    Eliquis100%
    Part D<11 patients
  • Respiratory

    23.9%
    Opioid Agonist23.9%
    Hydrocodone-Acetaminophen100%
    Part D<11 patients
Where care is delivered (Part B)19.5% facility · 80.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 1996–1996 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”